No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
VIR240517C10000
- 0.20
- +0.05+33.33%
15min DelayClose May 9 16:00 ET
0.20High0.20Low
0.20Open0.15Pre Close1 Volume285 Open Interest10.00Strike Price20.00Turnover64.26%IV6.69%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier8DDays to Expiry0.20Time Value100Contract SizeAmericanOptions Type0.3424Delta0.3984Gamma47.80Leverage Ratio-0.0215Theta0.0007Rho16.37Eff Leverage0.0053Vega
Intraday
- 5D
- 1D
News
Analysts' Top Healthcare Picks: Vir Biotechnology (VIR), Rocket Pharmaceuticals (RCKT)
Deep Dive Into Vir Biotechnology Stock: Analyst Perspectives (6 Ratings)
Across the recent three months, 6 analysts have shared their insights on Vir Biotechnology (NASDAQ:VIR), expressing a variety of opinions spanning from bullish to bearish.The table below provides a co
Express News | HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $110 Price Target
Analysts Just Shipped A Dazzling Upgrade To Their Vir Biotechnology, Inc. (NASDAQ:VIR) Estimates
Vir Biotechnology, Inc. (NASDAQ:VIR) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. The analysts greatly increased
Earnings Call Summary | Vir Biotechnology(VIR.US) Q1 2024 Earnings Conference
The following is a summary of the Vir Biotechnology, Inc. (VIR) Q1 2024 Earnings Call Transcript:Financial Performance:VIR Biotechnology reported a Q1 2024 total revenue of $56.4 million, a decline fr
Vir Biotechnology Is Maintained at Neutral by JP Morgan
Vir Biotechnology Is Maintained at Neutral by JP Morgan
Comments
$Vir Biotechnology(VIR.US$ They need better cost control and accounting practice to boost share price to a reasonable level (say 20). Section is bad because of Biden, but literally science is priced at 0 for VIR. Active investor should interfere. I’ll vote all Against in proxy, as I am not happy at all.
1
$Vir Biotechnology(VIR.US$ small scale experiments are good.
no idea why they issue cost guidance (huge) without revenue guidance. Stupid.
I don’t like new management goes back to clinical stage biotech. They hire too many people and relocate position to high salary area. AI expert in San Francisco, come on… If not sotrovimab and help of GSK made huge money, this company would have doomed.(if not stopped by Biden, would have been 40 dollar per share). I’ll start...
no idea why they issue cost guidance (huge) without revenue guidance. Stupid.
I don’t like new management goes back to clinical stage biotech. They hire too many people and relocate position to high salary area. AI expert in San Francisco, come on… If not sotrovimab and help of GSK made huge money, this company would have doomed.(if not stopped by Biden, would have been 40 dollar per share). I’ll start...
Morning Movers
Gapping up
$ZoomInfo(ZI.US$ The software stock popped 5.5% after Bank of America analyst Koji Ikeda upgraded it to buy from neutral. “We believe it is a classic self-help story that is set to outperform,” the analyst wrote, underscoring the company’s revenue growth reacceleration and new AI products as potential catalysts.
$Boeing(BA.US$ stock rose 0.9% after Ryanair, Europe's largest airline by passenger number...
Gapping up
$ZoomInfo(ZI.US$ The software stock popped 5.5% after Bank of America analyst Koji Ikeda upgraded it to buy from neutral. “We believe it is a classic self-help story that is set to outperform,” the analyst wrote, underscoring the company’s revenue growth reacceleration and new AI products as potential catalysts.
$Boeing(BA.US$ stock rose 0.9% after Ryanair, Europe's largest airline by passenger number...
20
$Cellectar BioSciences(CLRB.US$ Phase 2
$Regenxbio(RGNX.US$ Phase 2
$Leap Therapeutics(LPTX.US$ Phase 2
$4D Molecular Therapeutics(FDMT.US$ Phase 2
$Adverum Biotechnologies(ADVM.US$ Phase 2
$Denali Therapeutics(DNLI.US$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US$ Phase 2
$Xencor(XNCR.US$ Phase 2
$Harmony Biosciences(HRMY.US$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US$ Phase 2
$Disc Medicine(IRON.US$ Phase 2
$Atea Pharmaceuticals(AVIR.US$ Phase 2
$Allakos(ALLK.US$ Phase 2...
$Regenxbio(RGNX.US$ Phase 2
$Leap Therapeutics(LPTX.US$ Phase 2
$4D Molecular Therapeutics(FDMT.US$ Phase 2
$Adverum Biotechnologies(ADVM.US$ Phase 2
$Denali Therapeutics(DNLI.US$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US$ Phase 2
$Xencor(XNCR.US$ Phase 2
$Harmony Biosciences(HRMY.US$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US$ Phase 2
$Disc Medicine(IRON.US$ Phase 2
$Atea Pharmaceuticals(AVIR.US$ Phase 2
$Allakos(ALLK.US$ Phase 2...
36
6
The multiple insider sales in Vir Biotechnology and zero buying activity in the last year may be a concern for potential investors. However, a fair level of insider ownership suggests a reasonable alignment of interests with shareholders.
Read more
QianmengYuOP : not bad at GSK still sells somewhat and huge interest earnings. Regardless, free science
. I bought more near support 7.8 (need to fight together with other bulls) will buy more if going down to support.